1. participants who have any of the following conditions when screening: 1. alt or ast \> 5 uln; 2. scr \> 1.5 uln or ccr \< 50 ml/min; 3. tbil \> 2uln ; 4. hgb ≤ 90 g/ l; 5. plt ≤ 75×10\^9/ l; 2. participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except covid-19 virus infections; 3. participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents; 4. participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation; 5. participants who need a loading dose of anti-platelet drugs, such as aspirin (\>300 mg/day) and clopidogrel (\>300 mg/day); 6. participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months; 7. participants who have biliary obstruction; 8. female participants who are pregnant or breast-feeding or plan to be pregnant within this study period; 9. male participants whose wife or partner plan to be pregnant within this study period. 10. participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening; 11. participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening; 12. participants who have known allergies to any of the components used in the formulation of the interventions; 13. participants who have taken a part in a clinical study of an investigational intervention in the last 28 days. after 5 half-lives or 28 days, whichever is longer, can be allowed for screening; 14. participants who are not suitable for this trial, and with any medical condition will compromise their own safety.

1. participants who have any of the following conditions when screening: 1. alt or ast \> 5 uln; 2. scr \> 1.5 uln or ccr \< 50 ml/min; 3. tbil \> 2uln ; 4. hgb ≤ 90 g/ l; 5. plt ≤ 75×10\^9/ l; 2. participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except covid-19 virus infections; 3. participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents; 4. participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation; 5. participants who need a loading dose of anti-platelet drugs, such as aspirin (\>300 mg/day) and clopidogrel (\>300 mg/day); 6. participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months; 7. participants who have biliary obstruction; 8. female participants who are pregnant or breast-feeding or plan to be pregnant within this study period; 9. male participants whose wife or partner plan to be pregnant within this study period. 10. participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening; 11. participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening; 12. participants who have known allergies to any of the components used in the formulation of the interventions; 13. participants who have taken a part in a clinical study of an investigational intervention in the last 28 days. after 5 half-lives or 28 days, whichever is longer, can be allowed for screening; 14. participants who are not suitable for this trial, and with any medical condition will compromise their own safety.

participants who have any of the following conditions when screening: alt or ast > 5 uln; scr > 1.5 uln or ccr < 50 ml/min; tbil > 2uln ; hgb ≤ 90 g/ l; plt ≤ 75×10^9/ l; participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except covid-19 virus infections; participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents; participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation; participants who need a loading dose of anti-platelet drugs, such as aspirin (>300 mg/day) and clopidogrel (>300 mg/day); participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months; participants who have biliary obstruction; female participants who are pregnant or breast-feeding or plan to be pregnant within this study period; male participants whose wife or partner plan to be pregnant within this study period. participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening; participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening; participants who have known allergies to any of the components used in the formulation of the interventions; participants who have taken a part in a clinical study of an investigational intervention in the last 28 days. after 5 half-lives or 28 days, whichever is longer, can be allowed for screening; participants who are not suitable for this trial, and with any medical condition will compromise their own safety.

participants who have any of the following conditions when screening: alt or ast > 5 uln; scr > 1.5 uln or ccr < 50 ml/min; tbil > 2uln ; hgb ≤ 90 g/ l; plt ≤ 75×10^9/ l; participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except covid-19 virus infections; participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents; participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation; participants who need a loading dose of anti-platelet drugs, such as aspirin (>300 mg/day) and clopidogrel (>300 mg/day); participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months; participants who have biliary obstruction; female participants who are pregnant or breast-feeding or plan to be pregnant within this study period; male participants whose wife or partner plan to be pregnant within this study period. participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening; participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening; participants who have known allergies to any of the components used in the formulation of the interventions; participants who have taken a part in a clinical study of an investigational intervention in the last 28 days. after 5 half-lives or 28 days, whichever is longer, can be allowed for screening; participants who are not suitable for this trial, and with any medical condition will compromise their own safety.

participants who have any of the following conditions when screening: alt or ast > 5 uln; scr > 1.5 uln or ccr < 50 ml/min; tbil > 2uln ; hgb ≤ 90 g/ l; plt ≤ 100×10^9/ l; participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except covid-19 virus infections; participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents; participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation; participants who need long-term anti-platelet drugs, such as aspirin (>300 mg/day) and clopidogrel (>75 mg/day); participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months; participants who have biliary obstruction; female participants who are pregnant or breast-feeding or plan to be pregnant within this study period; male participants whose wife or partner plan to be pregnant within this study period. participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening; participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening; participants who have known allergies to any of the components used in the formulation of the interventions; participants who have taken a part in a clinical study of an investigational intervention in the last 30 days. after 5 half-lives or 30 days, whichever is longer, can be allowed for screening; participants who are not suitable for this trial, and with any medical condition will compromise their own safety.

participants who have any of the following conditions when screening: alt or ast > 5 uln; scr > 1.5 uln or ccr < 50 ml/min; tbil > 2uln ; hgb ≤ 90 g/ l; plt ≤ 100×10^9/ l; participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except covid-19 virus infections; participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents; participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation; participants who need long-term anti-platelet drugs, such as aspirin (>300 mg/day) and clopidogrel (>75 mg/day); participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months; participants who have biliary obstruction; female participants who are pregnant or breast-feeding or plan to be pregnant within this study period; male participants whose wife or partner plan to be pregnant within this study period. participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening; participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening; participants who have known allergies to any of the components used in the formulation of the interventions; participants who have taken a part in a clinical study of an investigational intervention in the last 30 days. after 5 half-lives or 30 days, whichever is longer, can be allowed for screening; participants who are not suitable for this trial, and with any medical condition will compromise their own safety.